BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34768395)

  • 41. Two novel polymorphisms in 5' flanking region of the mesothelin gene are associated with soluble mesothelin-related peptide (SMRP) levels.
    Cristaudo A; Foddis R; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Bruno R; Gemignani F; Landi S
    Int J Biol Markers; 2011; 26(2):117-23. PubMed ID: 21574151
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma.
    Bonotti A; Simonini S; Pantani E; Giusti L; Donadio E; Mazzoni MR; Chella A; Marconi L; Ambrosino N; Lucchi M; Mussi A; Cristaudo A; Foddis R
    Int J Biol Markers; 2017 Mar; 32(1):e126-e131. PubMed ID: 27646775
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Biomarkers for mesothelioma.
    Scherpereel A; Lee YC
    Curr Opin Pulm Med; 2007 Jul; 13(4):339-443. PubMed ID: 17534183
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mesothelin (MSLN) methylation and soluble mesothelin-related protein levels in a Chinese asbestos-exposed population.
    Yu M; Zhang Y; Jiang Z; Chen J; Liu L; Lou J; Zhang X
    Environ Health Prev Med; 2015 Sep; 20(5):369-78. PubMed ID: 26188910
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
    Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
    Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical significance of serum vascular endothelial growth factor in malignant pleural mesothelioma.
    Yasumitsu A; Tabata C; Tabata R; Hirayama N; Murakami A; Yamada S; Terada T; Iida S; Tamura K; Fukuoka K; Kuribayashi K; Nakano T
    J Thorac Oncol; 2010 Apr; 5(4):479-83. PubMed ID: 20357617
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical value of mesothelin in pleural effusions versus histology by medical thoracoscopy: brief report.
    Canessa PA; Ferro P; Manta C; Sivori M; Franceschini MC; Fedeli F; Roncella S
    Med Oncol; 2013; 30(3):649. PubMed ID: 23873013
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.
    Shiomi K; Hagiwara Y; Sonoue K; Segawa T; Miyashita K; Maeda M; Izumi H; Masuda K; Hirabayashi M; Moroboshi T; Yoshiyama T; Ishida A; Natori Y; Inoue A; Kobayashi M; Sakao Y; Miyamoto H; Takahashi K; Hino O
    Clin Cancer Res; 2008 Mar; 14(5):1431-7. PubMed ID: 18316566
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Significance of secretory leukocyte peptidase inhibitor in pleural fluid for the diagnosis of benign asbestos pleural effusion.
    Kishimoto T; Kojima Y; Fujimoto N
    Sci Rep; 2021 Jun; 11(1):12965. PubMed ID: 34155270
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Serum mesothelin for early detection of asbestos-induced cancer malignant mesothelioma.
    Creaney J; Olsen NJ; Brims F; Dick IM; Musk AW; de Klerk NH; Skates SJ; Robinson BW
    Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2238-46. PubMed ID: 20651076
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mesothelin promoter variants are associated with increased soluble mesothelin-related peptide levels in asbestos-exposed individuals.
    De Santi C; Pucci P; Bonotti A; Melaiu O; Cipollini M; Silvestri R; Vymetalkova V; Barone E; Paolicchi E; Corrado A; Lepori I; Dell'Anno I; Pellè L; Vodicka P; Mutti L; Foddis R; Cristaudo A; Gemignani F; Landi S
    Occup Environ Med; 2017 Jun; 74(6):456-463. PubMed ID: 28343162
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A predictive equation to adjust for clinical variables in soluble mesothelin-related protein (SMRP) levels.
    Park EK; Wilson D; Yates DH
    Clin Chem Lab Med; 2012 Dec; 50(12):2199-204. PubMed ID: 23093275
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Synchronous diffuse malignant mesothelioma and carcinomas in asbestos-exposed individuals.
    Attanoos RL; Thomas DH; Gibbs AR
    Histopathology; 2003 Oct; 43(4):387-92. PubMed ID: 14511258
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CCL2, galectin-3, and SMRP combination improves the diagnosis of mesothelioma in pleural effusions.
    Blanquart C; Gueugnon F; Nguyen JM; Roulois D; Cellerin L; Sagan C; Perigaud C; Scherpereel A; Gregoire M
    J Thorac Oncol; 2012 May; 7(5):883-9. PubMed ID: 22729037
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pleural Mesothelioma: Advances in Blood and Pleural Biomarkers.
    Sorino C; Mondoni M; Marchetti G; Agati S; Inchingolo R; Mei F; Flamini S; Lococo F; Feller-Kopman D
    J Clin Med; 2023 Nov; 12(22):. PubMed ID: 38002620
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Profiling tumor-associated markers for early detection of malignant mesothelioma: an epidemiologic study.
    Amati M; Tomasetti M; Scartozzi M; Mariotti L; Alleva R; Pignotti E; Borghi B; Valentino M; Governa M; Neuzil J; Santarelli L
    Cancer Epidemiol Biomarkers Prev; 2008 Jan; 17(1):163-70. PubMed ID: 18199721
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Plasma Fibulin-3 as a Potential Biomarker for Patients with Asbestos-Related Diseases in the Han Population.
    Jiang Z; Ying S; Shen W; He X; Chen J; Xia H; Yu M; Xiao Y; Feng L; Zhu L; Ju L; Guo X; Zhang Y; Shen JW; Tong Y; Zhang X; Lou J
    Dis Markers; 2017; 2017():1725354. PubMed ID: 29200597
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.
    Creaney J; Dick IM; Meniawy TM; Leong SL; Leon JS; Demelker Y; Segal A; Musk AW; Lee YC; Skates SJ; Nowak AK; Robinson BW
    Thorax; 2014 Oct; 69(10):895-902. PubMed ID: 25037982
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Follow-up of subjects occupationally exposed to asbestos, what are the objectives, the benefits, and the possible risks?].
    Dalphin JC
    Rev Mal Respir; 2011 Dec; 28(10):1230-40. PubMed ID: 22152932
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Malignant and non-malignant asbestos-related pleural and lung disease: 10-year follow-up study.
    Cvitanović S; Znaor L; Konsa T; Ivancević Z; Perić I; Erceg M; Vujović M; Vuković J; Beg-Zec Z
    Croat Med J; 2003 Oct; 44(5):618-25. PubMed ID: 14515425
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.